Medtronic Cuts FY26 EPS Guidance by Over 2% on MiniMed Flex Charge, Dilution
MDT is trading near its 52-week low of $79.55 (8.9% above the low).
Summary
Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 downwards to $5.50–$5.54, from the previous range of $5.62–$5.66. This reduction, representing over a 2% cut at the midpoint, is primarily attributed to a one-time $157 million charge, approximately $0.08 per share, related to future payments to Blackstone. The charge follows the FDA clearance of its MiniMed Flex smartphone-controlled insulin pump, a positive product development enabling earlier commercialization. Additionally, an IPO of 10% of MiniMed is expected to cause approximately $0.04 per share in dilution in Q4 FY26. While the FDA clearance is a positive, the financial impact of the charge and dilution leads to a negative outlook on near-term earnings. Traders will be watching for further details on the MiniMed Flex commercialization and any potential impact on the unchanged FY27 high single-digit EPS growth outlook.
At the time of this announcement, MDT was trading at $86.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $111.2B. The 52-week trading range was $79.55 to $106.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.